|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University of Texas Southwestern Medical Center Genentech |
| Information provided by: | University of Texas Southwestern Medical Center |
| ClinicalTrials.gov Identifier: | NCT00287443 |
Purpose
Our specific aims include:
| Condition | Intervention |
|
Cystic Fibrosis |
Procedure: Oral Glucose tolerance test Procedure: Whole body protein turnover Procedure: IV glucose tolerance test Procedure: Indirect Calorimetry Procedure: Dual Energy X-ray Absorptiometry (DEXA) Procedure: Growth Hormone Stimulation Test |
| Genetics Home Reference related topics: | cystic fibrosis |
| MedlinePlus related topics: | Cystic Fibrosis Diabetes |
| ChemIDplus related topics: | Dextrose Somatotropin Somatropin X-Rays |
| Study Type: | Interventional |
| Study Design: | Educational/Counseling/Training, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Estimated Enrollment: | 48 |
We will recruit 12 Hispanic prepubertal children with CF (ages 7-12, Tanner I) and 12 Hispanic adolescents (ages 15-17, Tanner 3 or 4) from the CF Centers at University of Texas Southwestern and Baylor College of Medicine in Houston. Information obtained from these subjects will be compared to 12 prepubertal and 12 adolescent Caucasian children with CF recruited from the same CF centers. We will categorize the subjects according to glucose tolerance (OGTT), as well as insulin secretion and insulin sensitivity using the IVGTT and the Minimal Model, as modified for children. We will also compare the historical information of socio-economic status and family history. Clinical status will be characterized by measuring pulmonary function and modified NIH scores, in addition to measuring levels of circulating cytokines. Gluconeogenesis (GNG) will be quantified by measuring the incorporation 2H into the 2nd, 5th and 6th carbons of glucose. Whole body protein turnover (WBPT) will be measured using [1-13C]leucine. Nutritional status will be determined by three-day food journals, and intake will be compared to energy needs, utilizing indirect calorimetry to measure resting energy expenditure. Subjects will be recruited from the CF centers at the University of Texas- Southwestern and the South Central CF Consortium.
Eligibility
| Ages Eligible for Study: | 7 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: Subjects will be required to be medically stable at the time of the study. Medical stability will be defined as:
Exclusion Criteria:
Contacts and Locations| United States, Texas | |||||
| Children’s Medical Center of Dallas | |||||
| Dallas, Texas, United States, 75390 | |||||
| University of Texas Southwestern Medical Center |
| Genentech |
| Principal Investigator: | Dana s HArdin | University of Texas Southwestern Medical Center at Dallas |
More Information
| Study ID Numbers: | 0303-161 |
| First Received: | February 2, 2006 |
| Last Updated: | February 2, 2006 |
| ClinicalTrials.gov Identifier: | NCT00287443 |
| Health Authority: | United States: Institutional Review Board |
|
|
|